[Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma].

Wu, L; Zhang, Y Z; Xia, B; Li, X W; Yuan, T; Tian, C; Zhao, H F; Yu, Y; Sotomayor, E

Wu, L; Zhang, Y Z; Xia, B; Li, X W; Yuan, T; Tian, C; Zhao, H F; Yu, Y; Sotomayor, E.

Afiliação

Wu L; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center For Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Zhang YZ; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center For Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.

Zhonghua Xue Ye Xue Za Zhi ; 38(12): 1036-1042, 2017 Dec 14.

Article em Zh | MEDLINE | ID: mdl-29365396

Assuntos

Linfoma Difuso de Grandes Células B; Células-Tronco Mesenquimais; Adenina/análogos & derivados; Animais; Linhagem Celular Tumoral; Humanos; Camundongos; Camundongos Endogâmicos NOD; Camundongos SCID; Piperidinas; Pirazóis; Pirimidinas; Receptores CXCR4

Palavras-chave

Chemokine CXCL12; Ibrutinib; Lymphoma, large B-cell, diffuse; Receptors, CXCR4

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Células-Tronco Mesenquimais Limite: Animals / Humans Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Ano de publicação: 2017 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google